The judge cited Shkreli’s “particularly heartless and coercive” tactics in monopolizing Daraprim and keeping generic rivals ...

The U.S. Supreme Court declined on Monday to hear former pharmaceutical company CEO Martin Shkreli's challenge to a $64.6 ...

The Supreme Court on Monday rejected a bid by notorious "pharma bro" Martin Shkreli to hear his appeal of a $64 million ...

The justices turned away Shkreli's appeal of a lower court's decision upholding the penalty, equal to the profits he and one ...

The U.S. Supreme Court decided on Monday not to take up Martin Shkreli’s appeal of a $64.6 million penalty he received after ...

The U.S. Supreme Court declined on Monday to review former pharmaceutical executive Martin Shkreli's challenge to a $64 ...

The Supreme Court on Monday rejected an appeal from Martin Shkreli, who was once dubbed “Pharma Bro” after jacking up the ...

One example is a high-profile matter against "pharma bro" Martin Shkreli, in which the U.S. District Court for the Eastern District of New York issued a preliminary injunction ordering him to hand ...

Martin Kaste is a correspondent on ... His privacy reporting was cited in the U.S. Supreme Court's 2012 United States v. Jones ruling concerning GPS tracking. Before moving to the West Coast ...

In the United States, both the Securities and Exchange Commission ... has been found to have what appears an unidentified page taken from the court documents that refer to a Supreme Court case that " ...

There were no generic alternatives to a lifesaving drug when Shkreli jacked up its price by more than $700 per pill in 2015.